Biopharma in India is Surging

According to this article in FierceBiotech a weakened economy and the need for cutbacks is pushing big pharma companies to drive drug development and manufacturing in India. One thing though, many Indian developers are having a hard time transitioning from manufacturing generic drugs to devising new therapies. This is certainly a huge opportunity for Indian firms to thrive if they can ease the transition somehow. It will be interesting to see how things will play out over the course of the next couple of years.

We're getting ready to launch a new blog that looks at the broader issues of clinical trials, providing breaking news, insights and strategies into clinical trials business and operations. Update your RSS feed now as we get it ready for our official launch:

http://clinicaltrialpartnerships.blogspot.com/